As a thought leader in Precision Medicine, Diaceutics CEO Peter Keeling has contributed to a pivotal paper outlining a roadmap for the potential use of innovative multicancer early detection (MCED) testing. The paper, published in Cancer on 15th February 2022, is the result of a two-year international collaboration led by global thought leaders.
“We believe the shift towards MCED, alongside single organ testing, fits our mission at Diaceutics to build an integrative platform (DXRX) focused on accelerating the adoption of impactful patient testing. Whilst the bar for introducing early cancer detection is high, we believe that addressing the “now recognized hurdles” at the front line, with practical multi-stakeholder collaborations, continues to be the right way to optimize the introduction of such disruptive test paradigms. We are delighted to have been part of this international body of experts and to be able to shape future thinking around the diffusion of this important paradigm shift. We believe our DXRX platform can play a pivotal supporting role,” commented Peter Keeling.